TMN

TMN is a highly non-specific acronym that refers to several distinct entities in biomedical research and clinical medicine. As a therapeutic agent, it primarily identifies an experimental **mitochondria-targeted aggregation-induced emission (AIE) photosensitizer** used in photodynamic therapy (PDT). This small molecule is designed to localize within the mitochondria and generate reactive oxygen species (ROS) upon light activation, inducing mitochondrial oxidative stress and triggering programmed cell death pathways such as pyroptosis and apoptosis. In preclinical oncology, it is often encapsulated in biomimetic nanoplatforms to improve tumor targeting and elicit immunogenic cell death (ICD). Additionally, 'TMN' is a standard abbreviation for **Transition Metal Nitrides**, a class of inorganic materials (e.g., Mo2N, VN, TiN) explored for their noble-metal-like electronic structures and catalytic properties in energy storage, drug delivery nanocarriers, and biosensing. In clinical oncology, 'tMN' (or TMN) denotes **therapy-related myeloid neoplasms**, which are secondary malignancies arising after cytotoxic cancer treatment. The acronym also refers to the **tuberomammillary nucleus** in neuroanatomy, **mean transit time** in cardiovascular physiology, and specific computational models like the **Temporal Mobile Network**.

Other names

Mitochondria-targeted AIEgen TMNTransition Metal NitridesTherapy-related Myeloid NeoplasmTuberomammillary NucleusMean Transit Time